TrialBlood advances2020

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).

Jeffrey E Lancet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.